KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Work In Process: 2018-2024

Historic Work In Process for Alnylam Pharmaceuticals (ALNY) over the last 7 years, with Dec 2024 value amounting to $65.0 million.

  • Alnylam Pharmaceuticals' Work In Process fell 49.18% to $35.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.5 million, marking a year-over-year decrease of 49.18%. This contributed to the annual value of $65.0 million for FY2024, which is 15.57% down from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Work In Process of $65.0 million as of FY2024, which was down 15.57% from $77.0 million recorded in FY2023.
  • Over the past 5 years, Alnylam Pharmaceuticals' Work In Process peaked at $113.8 million during FY2022, and registered a low of $16.1 million during FY2020.
  • Its 3-year average for Work In Process is $85.2 million, with a median of $77.0 million in 2023.
  • Its Work In Process has fluctuated over the past 5 years, first plummeted by 57.81% in 2020, then surged by 525.07% in 2021.
  • Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Work In Process stood at $16.1 million in 2020, then skyrocketed by 525.07% to $100.9 million in 2021, then grew by 12.72% to $113.8 million in 2022, then tumbled by 32.36% to $77.0 million in 2023, then decreased by 15.57% to $65.0 million in 2024.